PEAK6 Investments’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,500
Closed -$470K 6462
2022
Q1
$470K Sell
2,500
-13,400
-84% -$2.55M ﹤0.01% 3212
2021
Q4
$4.21M Sell
15,900
-20,200
-56% -$5.44M 0.01% 1271
2021
Q3
$10.4M Buy
+36,100
New +$9.26M 0.02% 677
2020
Q3
Sell
-15,000
Closed -$1.85M 4795
2020
Q2
$1.85M Buy
+15,000
New +$1.76M 0.01% 1551
2019
Q3
Sell
-21,800
Closed -$1.87M 4191
2019
Q2
$1.87M Buy
+21,800
New +$1.49M 0.01% 1345
2019
Q1
Sell
-26,200
Closed -$1.38M 4506
2018
Q4
$1.38M Sell
26,200
-31,400
-55% -$1.84M 0.01% 1501
2018
Q3
$3.19M Buy
+57,600
New +$2.97M 0.01% 1089

Other funds holding RGEN

PEAK6 Investments's RGEN Position: Q2 2023 in Review

PEAK6 Investments sold out of Repligen (RGEN) in Q2 2023, closing a stake of 291 shares — an estimated $49K sold.

PEAK6 Investments first reported a position in RGEN in Q1 2020 and held it in 9 quarters. The position peaked at $1.22M in Q1 2021. 448 funds tracked by Wall St. Rank hold RGEN as of Q2 2023.

  • PEAK6 Investments reported no remaining Repligen position as of Q2 2023 after selling out during the quarter.
  • PEAK6 Investments sold 291 Repligen shares in Q2 2023, an estimated $49K.
  • PEAK6 Investments first reported a position in Repligen in Q1 2020 and held it in 9 quarters.
  • PEAK6 Investments's Repligen position peaked at $1.22M in Q1 2021.
  • 448 funds tracked by Wall St. Rank held Repligen as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.